

**ADPC Treatment Subcommittee
MEETING MINUTES
4/27/2023**

Members Present:

	Craig Allen		Brynna Blackson	x	Kim Hougabook		Kathleen O'Connor		Cynthia Petronio-Vasquez
x	Maria Coutant-Skinner		Barbara Cass		Mark Jenkins	x	Gerard O'Sullivan	x	Kevin Shuler
x	Luiza Barnat		Wende Cooper	x	Heide Kapral		Dan Rezende	x	Joseph McKeon
x	Melissa Sienna		Deborah Daniel		Tara Kerner	x	Carl Schiessl	x	Katherine Ramos
	Robyn Anderson		Hilary Felton-Reid	x	Gabriela Krainer		Kristie Scott		
x	Herb Boyd		Julienne Girard		Chad McDonald		John Simoncelli		
	Maria Brereton	x	John Hamilton		Daniel Millstein	x	Danielle Warren-Dias		
	David Borzellino		Ally Kernan		Allyson Nadeau		John Lally		

TOPIC	DISCUSSION	ACTION ITEMS
Welcome & Intro of New Members/ Guests	None.	
Review of minutes	March 2023 minutes reviewed and accepted.	Approved
Opioid Settlement Advisory Committee (OSAC)	Katherine Ramos was re-introduced as OSAC program lead at DMHAS. Next meeting is May 9. Meeting/Committee information is on a dedicated website, working on public input portal on that site. The Committee is exploring how the ADPC will be involved, possibly as subject matter experts that make recommendations to the OSAC. There are five subcommittees to move the work forward. Research and evaluation subcommittee will vet recommended programs regarding their evidence-based status. Compliance and Finance subcommittee to ensure the recommendation is an allowable recommendation per Exhibit B. Public Participation subcommittee establishing guidelines for public input. Governance subcommittee is establishing bylaws.	
Treatment Implications of Xylazine	DPH monthly reports indicate Xylazine is present in about 25% of OCME certified deaths. Usually present with other drugs. Xylazine is changing conversations from ED's to harm reduction strategies – rescue breathing and CPR must go along with naloxone administration training, and wound care. Wounds not connected to injection sites may be breaking down. Wound care kits on the harm reduction rovers need to make sure to include information/education about Xylazine wounds that must be kept moist. Xylazine and fentanyl are newly federally classified as an emerging threat. Lack of point-of-service testing for fentanyl and xylazine is a clinical challenge (no CLIA-waived instant tests). Concern that test strips can promote use/types of use (i.e., injection drug use) among persons looking to use certain substances, like fentanyl, because of how the test must be performed (using liquified samples).	Maria to explore Xylazine presentation to this group.
Tracking Document Review	Review of not completed/partially completed goals for updates. <ul style="list-style-type: none"> Induction of patients on MOUD in medical settings. Progress being made on increasing access to MOUD/MAT within various medical settings. Many barriers have been removed (e.g., X Data Waiver). SNFs still do not have 	Maria to share recent article on ED inductions.

	<p>ability to serve someone on Methadone specifically. There is a workgroup meeting to address this issue, and how to build partnerships between SNFs/satellite MOUD providers. Preliminary discussions to hold a best practices conference (OTP/SNF collaboration). Note: Providers already are allowed to have a methadone van with licensure by DPH. Currently proposed bill places limit how the van operates.</p> <ul style="list-style-type: none"> • <u>Harm reduction</u>. Current goal is nearly completed, but more work on harm reduction remains to be done. The group may want to consider new harm reduction goals in the future to keep working on this issue. 	
New Business	<p>Heide Kapral advocated for increased information sharing and programming for families.</p> <p>NIDA Conference report out from John Hamilton: John Hamilton gave an overview presentation about stigma from recently attended NIDA conference.</p>	
MEMBER ANNOUNCEMENTS	None	
FUTURE RADAR	<ul style="list-style-type: none"> • OSAC recommendations/communication • Peer Recovery Support – keep on list because the committee has just started to meet • Trauma-informed treatment – Need a sponsor for Gabor Mate to come, keep on the radar • Co-occurring disorders treatment • Harm reduction centers – if move away from safe consumption there may be more support 	
UPCOMING MEETINGS	<p>Treatment Subcommittee: May 25th at 1pm</p> <p>ADPC Full Council: June 20th at 10am</p>	